Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Matsuda, Yoshinori; Narita, Shintaro; Nara, Taketoshi; Huang, Mingguo; Sato, Hiromi; Koizumi, Atsushi; Kanda, Sohei; Numakura, Kazuyuki; Saito, Mitsuru; Inoue, Takamitsu; Hiroshima, Yuko; Nanjo, Hiroshi; Satoh, Shigeru; Tsuchiya, Norihiko; Habuchi, Tomonori

doi:10.1186/s12885-020-06844-y

Cited by 12 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…YAP overexpression or increased activity may predict advanced tumour stages and poor clinical outcome in cancer patients 25,85,92 . A more recent discovery indicated that expression of nuclear YAP (nYAP) was noticeably upregulated in docetaxel‐resistant prostate cancer cell lines than parental cells 93 . Consistently, clinical data also revealed a higher nYAP level in the chemohormonal therapy (CHT) group than other groups, and patients with overexpressed nYAP in residual cancer after CHT predicted higher biochemical recurrence, indicating that nYAP level may be a promising prognostic factor in castration‐resistant prostate cancer patient treated with CHT 93 .…”

Section: The Clinical Significance Of Lncrnas Involved In Hippo Pathwmentioning

confidence: 99%

“…A more recent discovery indicated that expression of nuclear YAP (nYAP) was noticeably upregulated in docetaxel‐resistant prostate cancer cell lines than parental cells 93 . Consistently, clinical data also revealed a higher nYAP level in the chemohormonal therapy (CHT) group than other groups, and patients with overexpressed nYAP in residual cancer after CHT predicted higher biochemical recurrence, indicating that nYAP level may be a promising prognostic factor in castration‐resistant prostate cancer patient treated with CHT 93 . Furthermore, in conventional osteosarcoma, YAP/TAZ immune‐reactive score was significantly correlated with the overall survival (OS), and its nuclear expression was associated with progression‐free survival, 94 suggesting a prominent link between YAP/TAZ expression and osteosarcoma prognosis.…”

Section: The Clinical Significance Of Lncrnas Involved In Hippo Pathwmentioning

confidence: 99%

See 1 more Smart Citation

The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression

Yang

Lü

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

LncRNAs play a pivotal role in the regulation of epigenetic modification, cell cycle, differentiation, proliferation, migration and other physiological activities. In particular, considerable studies have shown that the aberrant expression and dysregulation of lncRNAs are widely implicated in cancer initiation and progression by acting as tumour promoters or suppressors. Hippo signalling pathway has attracted researchers’ attention as one of the critical cancer‐related pathways in recent years. Increasing evidences have demonstrated that lncRNAs could interact with Hippo cascade and thereby contribute to acquisition of multiple malignant hallmarks, including proliferation, metastasis, relapse and resistance to anti‐cancer treatment. Specifically, Hippo signalling pathway is reported to modulate or be regulated by widespread lncRNAs. Intriguingly, certain lncRNAs could form a reciprocal feedback loop with Hippo signalling. More speculatively, lncRNAs related to Hippo pathway have been poised to become important putative biomarkers and therapeutic targets in human cancers. Herein, this review focuses on the crosstalk between lncRNAs and Hippo pathway in carcinogenesis, summarizes the comprehensive role of Hippo‐related lncRNAs in tumour progression and depicts their clinical diagnostic, prognostic or therapeutic potentials in tumours.

show abstract

Section: The Clinical Significance Of Lncrnas Involved In Hippo Pathwmentioning

confidence: 99%

Section: The Clinical Significance Of Lncrnas Involved In Hippo Pathwmentioning

confidence: 99%

The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression

Yang

Lü

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…When the Hippo signaling pathway is activated, MST1 induces YAP phosphorylation in the presence of associated scaffolding proteins. When phosphorylated YAP accumulates in the cytoplasm, it is rapidly degraded by ubiquitination, thus exerting its effect of inducing apoptosis and inhibiting cell proliferation (15)(16)(17). Wang et al found that FFAR1 and FFAR4-dependent Hippo pathway activation mediated DHA-induced apoptosis in androgen non-dependent prostate cancer cells (18).…”

Section: Discussionmentioning

confidence: 99%

Effect of taurine on the proliferation, apoptosis and MST1/Hippo signaling in prostate cancer cells

Song

Yuan

Zhao

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: To investigate the effects of taurine on prostate cancer cell proliferation and apoptosis, and on the mammalian sterilization of a 20-like kinase-1 (MST1)/Hippo signaling pathway. Methods:The prostate cancer DU145 cell line was selected and the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) method was used to determine the rate of inhibition by taurine on the proliferation of the cells at 1, 10 −1 , 10 −2 , 10 −3 , 10 −4 , 10 −5 and 10 −6 mg/mL to obtain the taurine intervention concentrations. The cultured cells were divided into three groups: the blank group was cultured with conventional culture medium, the positive control group was cultured with 2 mg/mL cisplatin, and the taurine group was cultured with the determined taurine intervention concentrations of 0.003 mg/mL as low, 0.03 mg/mL as medium and 0.3 mg/mL as high concentration. After 72 h incubation, cell proliferation, apoptosis and cellular MST1/Hippo signaling pathway protein expression were observed.Results: In the comparison of cell proliferation rate, the taurine group was lower than the positive control group and the blank group (P<0.05), the cell proliferation rate of different concentrations in the taurine group decreased with the increase of concentration (P<0.05). The apoptosis rate was higher in the taurine group than in the positive control group and the blank group (P<0.05), the apoptosis rate increased with increasing concentration in the taurine group (P<0.05). The expression of MST1 and Bax was higher in the taurine group than in the positive control group and the blank group (P<0.05), the expression of MST1 and Bax increased with increasing concentration in the taurine group (P<0.05). The expression of YAP and Bcl-2 was lower in the taurine group than in the positive control group and the blank group (P<0.05), the expression of YAP and Bcl-2 decreased with increasing concentration in the taurine group (P<0.05).Conclusions: Taurine promoted apoptosis and inhibited proliferation of prostate cancer cells, and its mechanism of action may be related to the MST1/Hippo signaling pathway in a dose-dependent manner.

show abstract

“…Pathologic change of PCa after NCHT was not a significant factor of bPFS and OS in our study. Although previous report also demonstrated pathologic change of PCa after NCHT did not affect bPFS [ 12 ], further investigation of pathologic features of NCHT species could elucidate molecular target to predict the NCHT resistance [ 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Background: Radical prostatectomy (RP) is the standard treatment in patients with high-risk prostate cancer (PCa). However, there is a high rate of recurrence, and new approaches are required to improve surgical efficacy. Here, we evaluated the feasibility and safety of neoadjuvant chemohormonal therapy (NCHT) before RP for Japanese patients with high-risk localized prostate cancer (PCa). Methods: From February 2009 to April 2016, 21 high-risk patients were enrolled in this prospective study. Patients were treated with docetaxel (70 mg/m2) every four weeks for three cycles and luteinizing hormone-releasing hormone agonist. Patients with grade 3–4 toxicities had 25% dose reductions for the following course. Results: Median follow-up was 88.6 months. The dose of docetaxel was reduced in 13 patients. The estimated five-year biochemical progression-free survival (bPFS) rate was 57.1%. National Comprehensive Cancer Network criteria (high-risk, but not very high-risk (nVHR) versus VHR) was associated with bPFS (p = 0.03). Five-year bPFS rates in the nVHR and VHR groups were 76.9% and 25.0%, respectively. There was a significant difference in bPFS between the nVHR and VHR groups (p = 0.023) by Kaplan–Meier analysis. Conclusions: Although our study included a small number of cases, at least in our exploration, NCHT was safe and feasible. However, more extensive treatment modalities are needed to improve outcomes, especially in VHR patients.

show abstract

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Cited by 12 publications

References 49 publications

The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression

The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression

Effect of taurine on the proliferation, apoptosis and MST1/Hippo signaling in prostate cancer cells

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer

Contact Info

Product

Resources

About